Cancer Dictionary · Sarcoma

Soft Tissue and Bone Sarcoma

Sarcomas are divided into translocation-associated subtypes, which are defined by a specific fusion gene, and complex-karyotype subtypes, which carry chaotic genomes without a single defining event. Molecular testing is frequently part of establishing the diagnosis rather than a later addition, and specialist pathology review changes the diagnosis often enough that it is a standard recommendation.

Also called Soft tissue sarcoma, Osteosarcoma, Ewing sarcoma, Liposarcoma, Leiomyosarcoma.

Browse all entries Ask a question, free

Start here

The governing idea

Sarcoma is not one disease but more than a hundred, and getting the exact subtype right is the single most consequential step, because almost everything else follows from it.

01Before any molecular question

How it usually presents

Usually established first: the precise histological subtype, grade, site and size, and whether the tumour is resectable. Because these diagnoses are individually rare, review at a specialist sarcoma centre is routinely recommended, and it changes the diagnosis in a meaningful proportion of cases.

Usually already established

Precise histological subtype, ideally after specialist review
Grade, site and size
Resectability
Whether a defining fusion has been sought where the subtype suggests one

Major disease categories

The divisions below are not labels. Each one changes what the treatment discussion is actually about.

Translocation-associated sarcomas

Defined by a specific fusion: Ewing sarcoma, synovial sarcoma, myxoid liposarcoma, alveolar rhabdomyosarcoma and others. The fusion is diagnostic.

Complex karyotype sarcomas

Leiomyosarcoma, undifferentiated pleomorphic sarcoma, osteosarcoma and others. Chaotic genomes without a single defining alteration.

Well-differentiated and dedifferentiated liposarcoma

Defined by MDM2 and CDK4 amplification, which is diagnostically useful in distinguishing them from benign lipomatous tumours.

Gastrointestinal stromal tumour

Managed entirely separately from other sarcomas. See its own entry.

Bone sarcomas

Osteosarcoma, Ewing sarcoma and chondrosarcoma, each with distinct management.

Desmoid tumours

Locally aggressive but non-metastasising, with CTNNB1 alteration, and increasingly managed with observation rather than immediate intervention.

03What is discussed

Molecular considerations

In translocation-associated sarcomas, identifying the specific fusion confirms the diagnosis: EWSR1 fusions in Ewing sarcoma, SS18 fusions in synovial sarcoma, FUS-DDIT3 in myxoid liposarcoma, PAX3-FOXO1 in alveolar rhabdomyosarcoma. MDM2 and CDK4 amplification defines well-differentiated and dedifferentiated liposarcoma. NTRK fusions occur in infantile fibrosarcoma and other rare subtypes and are directly actionable. ALK fusions occur in inflammatory myofibroblastic tumour. SMARCB1 loss defines epithelioid sarcoma and rhabdoid tumours. Complex-karyotype sarcomas rarely yield a single actionable target.

Biomarkers commonly discussed

EWSR1, SS18, FUS, PAX3-FOXO1

Fusions that define specific sarcoma subtypes. Diagnostic rather than therapeutic.

MDM2 and CDK4

Amplification defines liposarcoma subtypes and distinguishes them from benign tumours.

NTRK

Fusions, rare but directly actionable and worth seeking in the right subtypes.

ALK

Fusions in inflammatory myofibroblastic tumour.

SMARCB1

Loss defines epithelioid sarcoma and rhabdoid tumours.

CTNNB1

Alteration in desmoid tumours.

TP53 and RB1

Frequently altered in complex-karyotype sarcomas. Descriptive.

This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.

04What is tested, and from what

Testing, inherited risk and blood-based monitoring

Genomic testing considerations

Fusion testing is often diagnostic rather than therapeutic in sarcoma, and it should be guided by which subtype is suspected. A panel that reads only point mutations is close to useless in a translocation-associated sarcoma. Comprehensive profiling is discussed in advanced disease, primarily to find NTRK or other rare actionable fusions and for trial access. Specialist pathology review is worth arranging before extensive testing, since it may change what should be tested.

Germline considerations

Several sarcomas are associated with inherited syndromes. Li-Fraumeni syndrome (TP53) is associated with osteosarcoma, soft tissue sarcoma and other early-onset cancers. Hereditary retinoblastoma (RB1) carries a substantially increased osteosarcoma risk. Neurofibromatosis type 1 predisposes to malignant peripheral nerve sheath tumours. Familial adenomatous polyposis is associated with desmoid tumours. Young age, multiple primaries, or a suggestive family history are the usual prompts, and sarcoma in a child or young adult is a recognised reason to consider Li-Fraumeni.

Cancer genetics and hereditary risk

ctDNA and liquid biopsy considerations

ctDNA is less established in sarcoma than in carcinomas, partly because fusion detection in plasma is technically harder than point mutation detection. It is an active research area, particularly in Ewing sarcoma and osteosarcoma where monitoring would be valuable.

When molecular information matters

Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.

Before treatment startsSpecialist pathology review is worth arranging, because the diagnosis changes in a meaningful proportion of cases and everything follows from it.
At diagnosisFusion testing confirms translocation-associated subtypes. Which test to order depends on which subtype is suspected.
In a young patient or with a family historyLi-Fraumeni and other syndromes are worth considering, since a finding affects the whole family.
In advanced diseaseComprehensive profiling is discussed for rare actionable fusions and for trial access.

06Take these to your team

Questions worth raising

When a decision is being made

Questions worth raising with a treating team.

Has the precise subtype been confirmed, ideally by a specialist sarcoma pathologist, since almost everything follows from it?
Has fusion testing been done where the suspected subtype is translocation-associated, using a method that can actually detect fusions?
Has NTRK been assessed in an appropriate subtype, since it is rare but directly actionable?
In a young patient, has an inherited syndrome such as Li-Fraumeni been considered?
Is care being coordinated through a centre that sees sarcoma regularly, given how rare these diagnoses individually are?

At progression, recurrence or resistance

The molecular picture at diagnosis is not always the molecular picture later.

Has the original diagnosis been revisited where behaviour does not match the expected pattern for that subtype?
Have trial options been reviewed, given how few standard options exist for many subtypes?

07What shapes eligibility

Clinical trial considerations

Trial eligibility is almost always written by precise subtype, and many trials are subtype-specific. This makes an accurate diagnosis the practical gateway to trial access in sarcoma more than in almost any other cancer.

Ask about trial matching

Plain-language glossary for this entry (4 terms)

Term	What it means
Translocation	When part of one chromosome joins another, creating a fusion gene. In many sarcomas this fusion defines the diagnosis.
Complex karyotype	A chaotic genome with many changes and no single defining event.
Specialist review	Having the pathology reassessed by a pathologist who specialises in sarcoma. Routinely recommended because it changes diagnoses.
Desmoid tumour	A locally aggressive tumour that does not spread to distant sites. Increasingly managed by observation.

Where OnKommon fits

These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.

Signature STt OProfiling from an existing FFPE tissue block.See how it works Signature STb O+The 523-gene comprehensive panel, with TMB and MSI.See how it works HeritageInherited-risk testing, and a tested pathway for relatives.See how it works Blueprint CareThe decision report that reads the profile and ranks the options.See how it works

This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.

Take the next step

Three ways forward. Pick the one that fits today.

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal